<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941019-2-00077</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Proposals must be received at the above address by November 18, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>National Cancer Institute; Opportunity for a Cooperative Research Agreement (CRADA) for the Scientific and Commercial Development of Monoclonal Antibodies to a Tumor-Specific Growth Factor for the Diagnosis and Prognosis of Premalignant Lesions and Cancer </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health, PHS, DHHS. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Readvertisement. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  This is a readvertisement of a notice which originally appeared in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  on August 16, 1994 (FR 59 42061&hyph;42062). Two changes are incorporated: The date for receipt of proposals has been extended and Item 8 under ``The role of the successful corporate partner *&blank;*&blank;*'' has been modified. The complete, revised text reads as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The National Cancer Institute (NCI) seeks a pharmaceutical or biotechnology company that can effectively pursue the scientific and commercial generation and development of a panel of monoclonal antibodies against an epidermal growth factor (EGF)-related peptide, cripto-1 (CR&hyph;1). The project is of scientific importance because CR&hyph;1 is a protein that exhibits structural homology to the EGF/transforming growth factor  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (TGF <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) gene family peptides. As such, CR&hyph;1 might function as a growth factor or growth inhibitor. Therefore, CR&hyph;1 may be important as an autocrine or paracrine modulator in such processes as tumor cell growth, wound repair, neovascularization, and inflammation.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> NCI has successfully isolated and cloned the gene that encodes CR&hyph;1, an EGF-related peptide growth factor that does not function through the EGF receptor. The NCI has also obtained a rabbit anti-peptide polyclonal antibody that can detect the expression of CR&hyph;1 in formalin-fixed, paraffin-embedded human tissue sections. CR&hyph;1 has been shown to be preferentially and differentially expressed in several different human premalignant lesions and cancers. The selected sponsor will purify a recombinant CR&hyph;1 protein and use this material as an immunogen to generate anti-CR&hyph;1 monoclonal antibodies for use in the diagnosis and prognosis of human cancers.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Inquiries and proposals regarding this opportunity should be addressed to either Michael Christini or Mark Noel (Tel  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> &sect;301&hyph;496&hyph;0477 Fax  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> 301&hyph;402&hyph;2117), Office of Technology Development, National Cancer Institute, Bldg. 31, Room 4A49, NIH, 9000 Rockville Pike, Bethesda, MD 20892.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Proposals must be received at the above address by November 18, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </DATE> <!-- PJG /STAG --></p>
		</main>
</body></html>
            